Exact Sciences Corporation (NASDAQ:EXAS) trading capacity remained 1.38 million shares during the last session. However, the volume average of the last three months is 2.78 million shares. The stock opened the day at $43.3, and settled at $45.42 by the end to experience a 3.79% change.Exact Sciences Corporation (EXAS) Analyst Opinion
Exact Sciences Corporation has a consensus outperform rating from 14 Wall Street analysts, and the number of shares currently sold short amount to at least 10.42% of shares outstanding. The stock sank -8.63% last month and is down -13.55 this year. Wall Street is only getting more bullish on the stock, with 8 of analysts who cover EXAS having a buy-equivalent rating. Analysts have placed a $58.82 price target on Exact Sciences Corporation, suggesting a 29.5% gain from recent close. It’s currently trading about -28.58% below its 52-week high.
Exact Sciences Corporation (EXAS) surprised the stock market in its last reported earnings when it earned -$0.18 a piece versus the consensus-estimated -$0.24. Its revenue totaled $85.74 million up 18.15% from the previous quarter.Exact Sciences Corporation (NASDAQ:EXAS) Intraday View
This stock (EXAS) is ahead of its 52-week low with 128.13%. Its last month’s stock price volatility remained 4.99% which for the week stands at 5.22%. The share price has moved backward from its 20 days moving average, trading at a distance of -2.58% and stays -9% away from its 50 days moving average. Over the last five days, shares have managed 7.2% gains and now is up 0.53% since hitting its 200-day moving average of $49.51. Exact Sciences Corporation (EXAS) has made its way to a 12-month gain of 102.14%.
Turning to Sangamo Therapeutics, Inc. (NASDAQ:SGMO), its shares were trading at $24.25 a gain of $0.75, on the trading floor. The stock, after opening at $23, touched a high of $24.3 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.9. Sangamo Therapeutics, Inc. has 2 buy ratings, 1 holds and 0 sells even after the stock tumbled -11.82% from its high of $27.50 to a $2.09 billion market value through last close.
The company’s consensus rating on Reuter’s scale remained unchanged from 1.86 to 1.86 during a month. Analysts set a 12-month price target of $21.8 a share. The target implies a -10.1% decrease from where the shares are currently trading. Also, the current price highlights a discount of 60.82% to analysts’ high consensus price target.Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Intraday Trading
The counter witnessed a trading volume of 2.35 million shares versus an average volume of 1.89 million shares during last trading session. Its last month’s stock price volatility remained 7.45% which for the week approaches 8.58%. The lowest price the stock reached in the last trading day was $22.8 and compares with the $3.85 52-week low. The stock recovered 529.87% since its low point and has performed 47.87% year-to-date.